Hemophilia A Concept

subject area of

• FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies  Journal Articles
• A Canadian survey of self‐infusion practices in persons with haemophilia A  Journal Articles
• A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada  Journal Articles
• A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A  Journal Articles
• A Practical Guide to the Management of the Fetus and Newborn With Hemophilia  Journal Articles
• A brief survey of clinicians’ perceptions of parent preferences for involvement in obstetrical and perinatal management decisions in haemophilia  Journal Articles
• A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients  Journal Articles
• A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients  Journal Articles
• A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred  Journal Articles
• A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates  Journal Articles
• A pilot randomized control trial to evaluate the feasibility of an Internet‐based self‐management and transitional care program for youth with haemophilia  Journal Articles
• A preliminary application of a haemophilia value framework to emerging therapies in haemophilia  Journal Articles
• A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose  Journal Articles
• A study of variations in the reported haemophilia A prevalence around the world  Journal Articles
• A survey of factor prophylaxis in the Canadian haemophilia A population  Journal Articles
• A survey of patients with haemophilia to understand how they track product used at home  Journal Articles
• A systematic review of definitions and reporting of bleeding outcome measures in haemophilia  Journal Articles
• A therapeutic alternative for haemophiliacs with inhibitors  Journal Articles
• AIDS in a patient with hemophilia receiving mainly cryoprecipitate.  Journal Articles
• ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease  Journal Articles
• ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease  Journal Articles
• Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years  Journal Articles
• Achieving the unimaginable: Health equity in haemophilia  Journal Articles
• Acquired Hemophilia A  Journal Articles
• Acquired Hemophilia A  Journal Articles
• Acquired hemophilia masked by warfarin therapy  Journal Articles
• Adherence with haemophilia treatments: a survey of haemophilia healthcare professionals in Canada  Journal Articles
• Adjusted dose continuous infusion of factor VIII in patients with haemophilia A  Journal Articles
• Adsorption of immunoglobulin G and anti-Factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes  Journal Articles
• Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward  Journal Articles
• Antibodies against Hepatitis C in a Population of Swedish Haemophiliacs and Heterosexual Partners  Journal Articles
• Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa  Journal Articles
• Assessments of outcome in haemophilia – a patient perspective  Journal Articles
• Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B  Journal Articles
• Association of patient, treatment and disease characteristics with patient‐reported outcomes: Results of the ECHO Registry  Journal Articles
• BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial  Journal Articles
• Bleeding disorders in neonates  Journal Articles
• Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review  Journal Articles
• Bleeding time in hemophilia a: Potential mechanisms for prolongation  Journal Articles
• Bone mineral density in haemophilia patients  Journal Articles
• Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders  Journal Articles
• Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science  Journal Articles
• Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?  Journal Articles
• Can evidence harm? Certainly not hemophilia treatment and community  Journal Articles
• Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada  Journal Articles
• Canadian multi‐institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT  Journal Articles
• Cardiovascular disease (CVD) in Canadians with haemophilia: Age‐Related CVD in Haemophilia Epidemiological Research (ARCHER study)  Journal Articles
• Cardiovascular disease prevalence and relevance in haemophilia: a scoping review  Journal Articles
• Care models in the management of haemophilia: a systematic review  Journal Articles
• Carrier detection in the hemophilias  Journal Articles
• Carrier detection of haemophilia A using DNA markers in families with an isolated affected male  Journal Articles
• Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families  Journal Articles
• Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada.  Journal Articles
• Cell Phones and Landlines: The Impact of Gene Therapy on the Cost and Availability of Treatment for Hemophilia  Journal Articles
• Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules  Journal Articles
• Central venous access device insertion and perioperative management of patients with severe haemophilia A  Journal Articles
• Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company  Journal Articles
• Characteristics of septic arthritis in human immunodeficiency virus- infected haemophiliacs versus other risk groups  Journal Articles
• Clinical application of Web Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS‐Hemo): Patterns of blood sampling and patient characteristics among clinician users  Journal Articles
• Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?  Journal Articles
• Clotting factor concentrate switching and inhibitor development in hemophilia A  Journal Articles
• Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice  Journal Articles
• Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population  Journal Articles
• Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?  Journal Articles
• Comparing bleed frequency and factor concentrate use between haemophilia A and B patients  Journal Articles
• Comparing hand‐held computers and paper diaries for haemophilia home therapy: a randomized trial  Journal Articles
• Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia  Journal Articles
• Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A  Journal Articles
• Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders  Journal Articles
• Concentrate‐related inhibitor risk: is a difference always real?  Journal Articles
• Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.  Journal Articles
• Confusion around the official classification of arthropathy  Journal Articles
• Continuous Infusion of Factor Concentrates: Review of Use in Hemophilia A and Demonstration of Safety and Efficacy in Hemophilia B  Conferences
• Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness  Journal Articles
• Continuous infusion  Conferences
• Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience  Journal Articles
• Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time  Journal Articles
• Coping Style in Relation to the Consumption of Factor Concentrate in HIV-Infected Hemophiliacs during the Years after Their Infection Became Known  Journal Articles
• Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH  Journal Articles
• Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project  Journal Articles
• Costs of on‐demand and prophylactic treatment for severe haemophilia in Norway and Sweden  Journal Articles
• Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada  Journal Articles
• DDAVP—The Multipotent Drug in Patients With Coagulopathies  Journal Articles
• Design and assessment of clinical trials on continuous infusion.  Conferences
• Developing a tracking system for coagulation factor concentrates in southern Ontario  Journal Articles
• Developing a two‐sided intervention to facilitate shared decision‐making in haemophilia: decision boxes for clinicians and patient decision aids for patients  Journal Articles
• Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup  Journal Articles
• Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization  Conferences
• Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project  Journal Articles
• Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors  Journal Articles
• Diagnosis and treatment of intracranial hemorrhage in children with hemophilia  Journal Articles
• Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment  Journal Articles
• Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A  Journal Articles
• Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A  Journal Articles
• Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?  Journal Articles
• Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A  Journal Articles
• Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.  Journal Articles
• Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A  Journal Articles
• Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.  Journal Articles
• Effects of factor VIII concentrates on the immune system in hemophilic patients  Journal Articles
• Efficacy and safety evaluation of Fanhdi^®, a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study  Journal Articles
• Efficacy of parenteral formulations of desmopressin in the treatment of bleeding disorders: A systematic review  Journal Articles
• Emicizumab state‐of‐the‐art update  Journal Articles
• Ensuring maximum outcomes and benefits in comprehensive care for bleeding disorders through surveillance and data collection  Journal Articles
• Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males  Journal Articles
• Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies  Journal Articles
• Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients  Journal Articles
• Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH  Journal Articles
• Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor  Journal Articles
• Evaluation of the sexual health in people living with hemophilia  Journal Articles
• Evaluation of the utility of the ISTH‐BAT in haemophilia carriers: a multinational study  Journal Articles
• Evidence about HUI and hemophilia in response to Young et al. “How well does the Canadian hemophilia outcomes‐kids' life assessment tool (CHO‐KLAT) measure the quality of life of boys with hemophilia?”  Journal Articles
• Evidence of a disability paradox in patient‐reported outcomes in haemophilia  Journal Articles
• Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU  Journal Articles
• Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS)  Journal Articles
• Experiences with continuous infusion of recombinant activated factor VII.  Conferences
• Exploring internet needs and use among adolescents with haemophilia: a website development project  Journal Articles
• Exploring regional variations in the cross‐cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study  Journal Articles
• Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics – impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment  Journal Articles
• FALSE NEGATIVE RESULT BY THE WELLCOZYME ANTI-HIV ASSAY IN TESTING AN HIV POSITIVE HAEMOPHILIAC  Journal Articles
• Factor VIII Products and Inhibitors in Severe Hemophilia A  Journal Articles
• Factor VIII concentrate for hemophilia: comparison of two heat-treated products.  Journal Articles
• Factor VIII products and inhibitors in severe hemophilia A.  Journal Articles
• Factor VIIa gets even bigger  Journal Articles
• Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes  Journal Articles
• Factors influencing therapeutic efficacy and the host immune response to helper‐dependent adenoviral gene therapy in hemophilia A mice  Journal Articles
• Factors responsible for ADP-induced release reaction of human platelets  Other
• Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach  Journal Articles
• Feasibility of Using Recombinant Factor VIIa in Continuous Infusion  Journal Articles
• First analysis of 10‐year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System  Journal Articles
• First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study  Journal Articles
• Gene Therapy for Hemophilia  Journal Articles
• Gene Therapy for Hemophilia: Addressing the Coming Challenges of Affordability and Accessibility  Journal Articles
• Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?  Journal Articles
• Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project  Journal Articles
• Global data and haemophilia care trends: commentary  Journal Articles
• HIV Infection in a Defined Population of Swedish Haemophiliacs  Journal Articles
• HIV‐serology and lymphocyte subsets in relation to therapy and clinical development in haemophiliacs  Journal Articles
• Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia  Journal Articles
• Haemophilia Experiences, Results and Opportunities (HERO) study: treatment‐related characteristics of the population  Journal Articles
• Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics  Journal Articles
• Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.  Journal Articles
• Haemophilia in a real‐world setting: the value of clinical experience in data collection  Journal Articles
• Haemophilia in the 1990s: Report of a Joint Meeting of the World Health Organization and World Federation of Hemophilia  Journal Articles
• Haemophilia prophylaxis: how can we justify the costs?  Journal Articles
• Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements  Journal Articles
• Handheld computers and paper diaries for documenting the use of factor concentrates used in haemophilia home therapy: a qualitative study  Journal Articles
• Health status and health‐related quality of life associated with hemophilia  Journal Articles
• Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy  Journal Articles
• Health utilities in adults with hemophilia A: A retrospective cohort study  Journal Articles
• Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1  Journal Articles
• Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders  Journal Articles
• Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A  Journal Articles
• Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.  Journal Articles
• Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.  Journal Articles
• Hemophilia gene therapy: first, do no harm  Journal Articles
• Hemophilia in the 1990s: Principles of Management and Improved Access to Care  Journal Articles
• Hepatitis C Infection in Patients With Hemophilia: Results of a National Survey  Journal Articles
• Hepatitis C Virus-infected, HCV-RNA-negative Patients with Bleeding Disorders - Relationship to Age, HIV and Treatment  Journal Articles
• Hepatitis C genotypes in Australian haemophilia patients  Journal Articles
• Hepatitis E virus infection in hemophiliacs  Journal Articles
• Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden  Journal Articles
• Heterogeneity of information regarding inhibitors in the product monographs of antihaemophilic factors in North America  Journal Articles
• Heterogeneity of the immune response to adenovirus‐mediated factor VIII gene therapy in different inbred hemophilic mouse strains  Journal Articles
• High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs  Journal Articles
• High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C.  Journal Articles
• High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance  Journal Articles
• Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process  Journal Articles
• Humanistic burden of problem joints for children and adults with haemophilia  Journal Articles
• IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII  Journal Articles
• Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts  Journal Articles
• Immune response to multiple skin test antigens in haemophiliacs.  Journal Articles
• Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.  Journal Articles
• Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B  Journal Articles
• Immunodepletion of human plasma factor VIII  Journal Articles
• Immunogenicity, efficacy and safety of Nuwiq^® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study  Journal Articles
• Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up  Journal Articles
• Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study  Journal Articles
• Improving comprehensive care in the haemophilia community: building on the HERO Study  Journal Articles
• Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.  Journal Articles
• Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products  Journal Articles
• Individualizing Factor Replacement Therapy in Severe Hemophilia  Journal Articles
• Inhibitor development in haemophilia according to concentrate  Journal Articles
• Inhibitor development in non-severe haemophilia across Europe  Journal Articles
• Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression  Journal Articles
• Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases  Journal Articles
• Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors  Journal Articles
• Joint WFH‐ISTH session: issues in clinical trial design  Journal Articles
• Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics  Journal Articles
• Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans  Journal Articles
• Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more  Journal Articles
• Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia  Journal Articles
• Limited Protective Effect of the CCR5Δ32/CCR5Δ32 Genotype on Human Immunodeficiency Virus Infection Incidence in a Cohort of Patients with Hemophilia and Selection for Genotypic X4 Virus  Journal Articles
• Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients  Journal Articles
• Low Dose Prophylaxis vis-a-vis on-Demand Treatment Strategies for Hemophilia: A Cost Effective and Disability Attenuating Approach.  Journal Articles
• Low prevalence of inhibitor antibodies in the Canadian haemophilia population  Journal Articles
• Lower-dose emicizumab prophylaxis: can less be more?  Journal Articles
• Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada  Journal Articles
• Major surgery seems not to influence HIV disease progression in haemophilia patients  Journal Articles
• Management of bleeding disorders: basic science  Journal Articles
• Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data  Journal Articles
• Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa  Journal Articles
• Methodology for the development of the NHF‐McMaster Guideline on Care Models for Haemophilia Management  Journal Articles
• Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH  Journal Articles
• Monkey business for hemophilia management  Journal Articles
• Monoclonal Purified F VIII for Continuous Infusion: Stability, Microbiological Safety and Clinical Experience  Journal Articles
• More on: are randomized clinical trials the only truth? Not always  Journal Articles
• Mortality and causes of death in Italian persons with haemophilia, 1990–2007  Journal Articles
• Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up  Journal Articles
• Multicentre pharmacokinetic evaluation of rFVIII‐Fc (efmoroctocog alfa) in a real life and comparison with non‐extended half‐life FVIII concentrates  Journal Articles
• Multiple Joint Procedures in a Single Operative Session on Hemophilic Patients  Journal Articles
• Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study  Journal Articles
• Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran  Conferences
• Myositis ossificans in hemophilia  Journal Articles
• NHF‐McMaster Guideline on Care Models for Haemophilia Management  Journal Articles
• Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series  Journal Articles
• New developments in laboratory diagnosis and monitoring  Journal Articles
• No Evidence for Vertical Transmission in Children Born to HIV Seropositive Male Haemophiliacs  Journal Articles
• Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B  Journal Articles
• Nonviral Gene Therapy Approaches to Hemophilia  Journal Articles
• Non‐severe haemophilia: Is it benign? – Insights from the PROBE study  Journal Articles
• North American Study of Factor VIII Concentrate Potency  Journal Articles
• Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma‐derived solvent‐detergent factor VIII concentrate  Journal Articles
• On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome  Journal Articles
• Oral Corticosteroid Therapy as an Adjuvant Treatment for Acute Bleeding in Hemophilia Patients With High Titer Inhibitors  Journal Articles
• Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care  Journal Articles
• Orthotopic liver transplantation in a patient with combined hemophilia A and B  Journal Articles
• Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders  Journal Articles
• Outcomes indicators and processes in transitional care in adolescents with haemophilia: A Delphi survey of Canadian haemophilia care providers  Journal Articles
• Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes  Journal Articles
• Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM  Journal Articles
• Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment  Journal Articles
• Patients’, physicians’, and pharmacists’ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study  Journal Articles
• Patterns of joint damage in severe haemophilia A treated with prophylaxis  Journal Articles
• Performance of recalibrated ReFacto^® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one‐stage assays after infusion of recalibrated ReFacto^® (B‐domain deleted recombinant factor VIII)  Journal Articles
• Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH  Journal Articles
• Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study  Journal Articles
• Pharmacokinetics of recombinant and plasma‐derived factor VIII products in paediatric patients with severe haemophilia A  Journal Articles
• Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium  Journal Articles
• Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C)  Journal Articles
• Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation  Journal Articles
• Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation  Journal Articles
• Point‐of‐care ultrasonography in haemophilia care: Training and competency for muscular haematomas  Journal Articles
• Prevalence of hepatitis C virus infection among patients with inherited bleeding disorders in Newfoundland.  Journal Articles
• Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized  Journal Articles
• Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature  Journal Articles
• Psychological interventions for people with hemophilia  Journal Articles
• Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire  Journal Articles
• Psychosocial Self-Prognosis in Relation to Mortality and Morbidity in Hemophiliacs with HIV Infection  Journal Articles
• Psychosocial aspects of haemophilia: a systematic review of methodologies and findings  Journal Articles
• Pulmonary Hypertension in Hemophilia  Journal Articles
• Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls  Journal Articles
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review  Journal Articles
• Recombinant Factor VIIa in Multiple Surgery  Journal Articles
• Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study  Journal Articles
• Recombinant factor VIII concentrate  Journal Articles
• Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors  Journal Articles
• Recombination between the factor VIII gene and the DXS52 locus gives the most probable genetic order as centromere‐FRA(X)‐DXS15‐DXS52‐F8C‐telomere  Journal Articles
• Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH  Journal Articles
• Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group  Journal Articles
• Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference  Journal Articles
• Redefining Disease? The Nosologic Implications of Molecular Genetic Knowledge  Journal Articles
• Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A  Journal Articles
• Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates  Journal Articles
• Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice  Journal Articles
• Reported prevalence of von Willebrand disease worldwide in relation to income classification  Journal Articles
• Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development  Journal Articles
• Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study  Journal Articles
• Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature  Journal Articles
• Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List  Journal Articles
• Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients  Conferences
• SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY  Journal Articles
• Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting  Journal Articles
• Safety, efficacy and lessons from continuous infusion with rFVIIa  Conferences
• Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.  Journal Articles
• Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers  Journal Articles
• Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study  Journal Articles
• Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study  Journal Articles
• Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study  Journal Articles
• Social Support and the Development of Immune Function in Human Immunodeficiency Virus Infection  Journal Articles
• Sonography for assessment of haemophilic arthropathy in children: a systematic protocol  Journal Articles
• Suggestions for the management of factor VIII inhibitors  Journal Articles
• Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement Therapy  Journal Articles
• Survey of the Canadian hemophilia population.  Journal Articles
• Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity  Journal Articles
• Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics  Journal Articles
• Switching patients in the age of long-acting recombinant products?  Journal Articles
• Switching to extended half‐life products in Canada – preliminary data  Journal Articles
• THE TREATMENT OF HAEMOPHILIA A WITH ANTI‐HAEMOPHILIC FACTOR  Journal Articles
• Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort  Journal Articles
• Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study  Journal Articles
• Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement  Journal Articles
• Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database  Journal Articles
• Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study  Conferences
• The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates  Journal Articles
• The International Registry of Immune Tolerance: 1994 Update  Conferences
• The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters  Journal Articles
• The World Federation of Hemophilia Annual Global Survey 1999‐2018  Journal Articles
• The current state of adverse event reporting in hemophilia  Journal Articles
• The demographics, treatment characteristics and quality of life of adult people with haemophilia in China – results from the HERO study  Journal Articles
• The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies  Journal Articles
• The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A  Journal Articles
• The factor VIII-independent activation of factor X by factors IXa and VII in plasma  Journal Articles
• The haemophilia certification system in Canada.  Journal Articles
• The importance of haemophilia treatment centre administrators in patient care  Journal Articles
• The national haemophilia program standards, evaluation and oversight systems in the United States of America.  Journal Articles
• The onerous task of comparing treatments in inhibitor patients  Journal Articles
• The plasma concentration of activated protein C appears normal in patients with haemophilia  Journal Articles
• The role of telemedicine in the delivery of health care in the COVID‐19 pandemic  Journal Articles
• The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey  Journal Articles
• The value of usability testing for Internet-based adolescent self-management interventions: “Managing Hemophilia Online”  Journal Articles
• The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A  Journal Articles
• Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A  Journal Articles
• Thrombin generation in vitro in the presence of by‐passing agents in siblings with severe haemophilia A  Journal Articles
• Tissue factor microparticles and haemophilia  Journal Articles
• Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1  Journal Articles
• Total thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen and pro‐TAFI in patients with haemophilia A  Journal Articles
• Towards comprehensive care in transition for young people with haemophilia  Journal Articles
• Transmission of HIV Infection to Heterosexual Partners but Not to Household Contacts of Seropositive Haemophiliacs  Journal Articles
• Transmission of hepatitis C with pasteurised factor VIII  Journal Articles
• Treatment decision‐making among Canadian youth with severe haemophilia: a qualitative approach  Journal Articles
• Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme  Journal Articles
• Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A  Journal Articles
• Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010  Journal Articles
• Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study  Journal Articles
• Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A  Journal Articles
• Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A  Journal Articles
• Using pharmacokinetics to individualize hemophilia therapy  Journal Articles
• Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders  Journal Articles
• Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia  Journal Articles
• Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders  Journal Articles
• Validation of a composite score for clinical severity of hemophilia  Journal Articles
• Von Willebrand Disease: Gaining a global perspective  Journal Articles
• WFH – the cornerstone of global development: 45 years of progress  Journal Articles
• What is a cure and how do we get there?  Journal Articles
• What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia  Journal Articles
• What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers  Journal Articles
• World Federation of Hemophilia Gene Therapy Registry  Journal Articles
• World Federation of Hemophilia: 50 years of advancing treatment for all  Journal Articles
• World bleeding disorders registry: The pilot study  Journal Articles
• [Centralized care is the basis of care programs for hemophilia patients].  Journal Articles
• [Cure of hemophilia is approaching. Gene therapy is the hope].  Journal Articles
• [Desmopressin--an effective agent in many hemorrhagic disorders].  Journal Articles
• [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].  Journal Articles